Immucell Corp (ICCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,157 | -5,775 | -2,494 | -78 | -1,022 |
| Depreciation Amortization | 2,730 | 2,740 | 2,495 | 2,469 | 2,450 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | -15 |
| Accounts receivable | -1,586 | -427 | 936 | -897 | -160 |
| Accounts payable and accrued liabilities | 363 | 157 | 342 | 246 | 300 |
| Other Working Capital | -407 | -2,112 | -1,833 | -1,623 | 532 |
| Other Operating Activity | 1,414 | 743 | -990 | 838 | -770 |
| Operating Cash Flow | $358 | $-4,674 | $-1,544 | $954 | $1,316 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 996 | 1,457 |
| PPE Investments | -461 | -1,890 | -3,964 | -2,593 | -4,027 |
| Investing Cash Flow | $-461 | $-1,890 | $-3,964 | $-1,597 | $-2,570 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | 5,000 | 2,000 | 400 | 11,538 |
| Common Stock Issued | 4,648 | 19 | 31 | 4,245 | 0 |
| Other Financing Activity | -1,765 | -3,267 | -917 | -766 | -9,627 |
| Financing Cash Flow | $2,883 | $1,752 | $1,114 | $3,879 | $1,911 |
| Beginning Cash Position | 979 | 5,792 | 10,186 | 6,950 | 6,293 |
| End Cash Position | 3,758 | 979 | 5,792 | 10,186 | 6,950 |
| Net Cash Flow | $2,780 | $-4,813 | $-4,394 | $3,236 | $657 |
| Free Cash Flow | |||||
| Operating Cash Flow | 358 | -4,674 | -1,544 | 954 | 1,316 |
| Capital Expenditure | -466 | -1,893 | -3,975 | -2,609 | -4,073 |
| Free Cash Flow | -108 | -6,567 | -5,519 | -1,654 | -2,757 |